Evidence map›Paper›PMID 41608774›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2026

Whole-Body Knockout of the AhR (Aryl Hydrocarbon Receptor) Ameliorates Atherosclerosis Due to Altered Lipid Metabolism-Brief Report.

Rosanna Huchzermeier, Renske J de Jong, Leonida Rakateli, Andrea Bonnin-Marquez, Sanne L Maas, Chantal Maassen-Pöttgens, Kathrin Abschlag, Han Jin, Anna-Lena Geiselhöringer, Vasiliki Triantafyllidou and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rosanna Huchzermeier *Institute for Molecular Cardiovascular Research, Uniklinik RWTH Aachen (R.H., L.R., A.B.-M., S.L.M., C.M.-P., K.A., J.J., E.A.L.B., E.P.C.v.d.V.), RWTH Aachen University, Germany.ORCID 0009-0007-8022-3421
Renske J de Jong *Department of Pediatrics (R.J.d.J.), RWTH Aachen University, Germany.ORCID 0009-0009-6093-3906
Leonida RakateliInstitute for Molecular Cardiovascular Research, Uniklinik RWTH Aachen (R.H., L.R., A.B.-M., S.L.M., C.M.-P., K.A., J.J., E.A.L.B., E.P.C.v.d.V.), RWTH Aachen University, Germany.
Andrea Bonnin-MarquezInstitute for Molecular Cardiovascular Research, Uniklinik RWTH Aachen (R.H., L.R., A.B.-M., S.L.M., C.M.-P., K.A., J.J., E.A.L.B., E.P.C.v.d.V.), RWTH Aachen University, Germany.ORCID 0000-0002-4165-1403
Sanne L MaasInstitute for Molecular Cardiovascular Research, Uniklinik RWTH Aachen (R.H., L.R., A.B.-M., S.L.M., C.M.-P., K.A., J.J., E.A.L.B., E.P.C.v.d.V.), RWTH Aachen University, Germany.ORCID 0000-0003-1423-8901
Chantal Maassen-PöttgensInstitute for Molecular Cardiovascular Research, Uniklinik RWTH Aachen (R.H., L.R., A.B.-M., S.L.M., C.M.-P., K.A., J.J., E.A.L.B., E.P.C.v.d.V.), RWTH Aachen University, Germany.
Kathrin AbschlagInstitute for Molecular Cardiovascular Research, Uniklinik RWTH Aachen (R.H., L.R., A.B.-M., S.L.M., C.M.-P., K.A., J.J., E.A.L.B., E.P.C.v.d.V.), RWTH Aachen University, Germany.
Han JinCentral Laboratory, Tianjin Medical University General Hospital, China (H.J.).
Anna-Lena GeiselhöringerCenter of Allergy and Environment (ZAUM), Technical University and Helmholtz Center Munich, Germany (R.J.d.J., A.-L.G., C.O.).ORCID 0009-0000-3054-8446
Vasiliki TriantafyllidouInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany (V.T., D.S., E.P.C.v.d.V.).
Donato SantovitoInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany (V.T., D.S., E.P.C.v.d.V.).ORCID 0000-0003-1811-4746
Joachim JankowskiInstitute for Molecular Cardiovascular Research, Uniklinik RWTH Aachen (R.H., L.R., A.B.-M., S.L.M., C.M.-P., K.A., J.J., E.A.L.B., E.P.C.v.d.V.), RWTH Aachen University, Germany.ORCID 0000-0002-4528-2967
Erik A L BiessenInstitute for Molecular Cardiovascular Research, Uniklinik RWTH Aachen (R.H., L.R., A.B.-M., S.L.M., C.M.-P., K.A., J.J., E.A.L.B., E.P.C.v.d.V.), RWTH Aachen University, Germany.ORCID 0000-0002-6454-8548
Caspar OhnmachtCenter of Allergy and Environment (ZAUM), Technical University and Helmholtz Center Munich, Germany (R.J.d.J., A.-L.G., C.O.).
Emiel P C van der VorstInstitute for Molecular Cardiovascular Research, Uniklinik RWTH Aachen (R.H., L.R., A.B.-M., S.L.M., C.M.-P., K.A., J.J., E.A.L.B., E.P.C.v.d.V.), RWTH Aachen University, Germany.ORCID 0000-0001-5771-6278

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAtherosclerotic cardiovascular disease, characterized by an imbalanced lipid metabolism and a dysregulated immune response, is a major cause of death worldwide. The AhR (aryl hydrocarbon receptor) is a ligand-activated transcription factor that is highly expressed in the liver and primarily known for its role in detoxification. However, recent studies suggest that the AhR also plays a key role in immune regulation, indicating that this receptor can influence the development of atherosclerosis.

methods

resultsThe number of circulating leukocytes was increased in

conclusionsOur study demonstrates a remarkable role for AhR in the pathogenesis of atherosclerosis, interfering with both lipid metabolism and inflammatory pathways. Although the underlying mechanisms remain unclear, these results demonstrate a novel and crucial role for AhR in atherosclerotic cardiovascular disease.

Indexed as

atherosclerosiscardiovascular diseaseslipid metabolismmice, knockoutreceptors, aryl hydrocarbon

Identifiers

PMID41608774
PMCPMC12931860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.